Before joining Adocia in August, Glezer worked for about one year as Vice President, Medical Affairs, at the Danish company Novo Nordisk. In his new position he will be in charge of the clinical development of Adocias portfolio of novel treatments for diabetes, which ranges from preclinical to pre-phase 3 assets. „Glezers outstanding track-record in clinical development, product launch, and medical affairs with industry-leading companies in diabetes is a significant asset for Adocia,” commented Gérard Soula, Chairman and CEO of Adocia. “In particular, as a Global Leader for Toujeo he has garnered invaluable expertise on the development and launch of an innovative formulation of an approved insulin. These skills are extremely relevant to our innovative projects based on BioChaperone technology.”

Previously Glezer worked at Novo Nordisk and held several positions at Sanofi. Among others, he was the Global Leader for the Toujeo Project. A next-generation method to administer basal insulin subcutaneously, based on a broadly-used molecule (insulin glargine).